Cargando…

Androgen deprivation therapy for prostate cancer and the risk of hematologic disorders

PURPOSE: This study aimed to investigate the association between androgen deprivation therapy (ADT) and the risk of subsequently developing hematologic disorders in patients with prostate cancer. MATERIALS AND METHODS: This population-based nationwide cohort study utilized data from the Taiwan Natio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Jui-Ming, Liu, Yueh-Ping, Chuang, Heng-Chang, Wu, Chun-Te, Su, Yu-Li, Hsu, Ren-Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7029847/ https://www.ncbi.nlm.nih.gov/pubmed/32074125 http://dx.doi.org/10.1371/journal.pone.0229263

Ejemplares similares

Decreased Risk of Renal Calculi in Patients Receiving Androgen Deprivation Therapy for Prostate Cancer
por: Lin, Chien-Yu, et al.
Publicado: (2020)

No increased risk of psoriasis in patients receiving androgen deprivation therapy for prostate cancer: a 17-year population-based study
por: Liu, Jui-Ming, et al.
Publicado: (2018)

Association between Androgen Deprivation Therapy and Risk of Dementia in Men with Prostate Cancer
por: Liu, Jui-Ming, et al.
Publicado: (2021)

Association between Helicobacter pylori infection and mortality risk in prostate cancer patients receiving androgen deprivation therapy: A real‐world evidence study
por: Liu, Jui‐Ming, et al.
Publicado: (2021)

Type of Androgen Deprivation Therapy and Risk of Dementia Among Patients With Prostate Cancer in Taiwan
por: Huang, Wen-Kuan, et al.
Publicado: (2020)

Androgen deprivation therapy and the risk of subsequent keratitis
por: Liu, Dai-Wei, et al.
Publicado: (2020)

Prostate cancer, insulin, and androgen deprivation therapy
por: Stattin, P, et al.
Publicado: (2003)

Changes in prostate-specific antigen kinetics during androgen-deprivation therapy as a predictor of response to abiraterone in chemonaïve patients with metastatic castration-resistant prostate cancer
por: Lee, Chung-Lin, et al.
Publicado: (2022)

The Response of Prostate Cancer to Androgen Deprivation and Irradiation Due to Immune Modulation
por: Wu, Chun-Te, et al.
Publicado: (2018)

Androgen Deprivation Therapy and Cardiovascular Risk in Chinese Patients with Nonmetastatic Carcinoma of Prostate
por: Huang, Gang, et al.
Publicado: (2014)

Reply: Prostate cancer, insulin and androgen deprivation therapy
por: Lehrer, S
Publicado: (2003)

Androgen deprivation therapy for prostate cancer and risk of dementia
por: Robinson, David, et al.
Publicado: (2019)

Androgen deprivation therapy in high risk prostate cancer
por: Van Dams, Ritchell, et al.
Publicado: (2019)

Cardiovascular Risks of Androgen Deprivation Therapy for Prostate Cancer
por: Corona, Giovanni, et al.
Publicado: (2021)

Androgen deprivation therapy as backbone therapy in the management of prostate cancer
por: Merseburger, Axel S, et al.
Publicado: (2016)

Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
por: Fujimoto, Naohiro, et al.
Publicado: (2011)

Androgen deprivation therapy and fracture risk in Chinese patients with prostate carcinoma
por: Lee, Chi-Ho, et al.
Publicado: (2017)

Prostate-Specific Antigen Kinetics Effects on Outcomes of Low-Volume Metastatic Prostate Cancer Patients Receiving Androgen Deprivation Therapy
por: Lin, Yen-Chi, et al.
Publicado: (2021)

Medication utilization evaluation of androgen deprivation therapy for prostate cancer in Taiwan
por: Liao, Kuang-Ming, et al.
Publicado: (2020)

Risk of ischemic stroke in patients with prostate cancer receiving androgen deprivation therapy in Taiwan
por: Liao, Kuang-Ming, et al.
Publicado: (2019)

Androgen deprivation therapy and the risk of iron-deficiency anaemia among patients with prostate cancer: a population-based cohort study
por: Wu, Fang-Jen, et al.
Publicado: (2020)

The clinical guiding value of a radiomics model for androgen deprivation therapy for prostate cancer
por: Yu, Na, et al.
Publicado: (2021)

Prostate-selective α antagonists increase fracture risk in prostate cancer patients with and without a history of androgen deprivation therapy: a nationwide population-based study
por: Kao, Wei-Heng, et al.
Publicado: (2018)

Androgen deprivation and cognition in prostate cancer
por: Salminen, E, et al.
Publicado: (2003)

Impact of Androgen Deprivation on Oxidative Stress and Antioxidant Status in Nigerian Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy
por: Bassey, Iya Eze, et al.
Publicado: (2020)

An Update on the Changing Indications for Androgen Deprivation Therapy for Prostate Cancer
por: Myklak, Kristene, et al.
Publicado: (2011)

Metabolomic effects of androgen deprivation therapy treatment for prostate cancer
por: Chi, Jen‐Tsan, et al.
Publicado: (2020)

Relugolix – The novel oral androgen deprivation therapy for prostate cancer
por: Jena, Rahul
Publicado: (2020)

Adjuvant androgen deprivation therapy for prostate cancer treated with radiation therapy
por: Siddiqui, Zaid A., et al.
Publicado: (2018)

Patients receiving androgen deprivation therapy for prostate cancer have an increased risk of depressive disorder
por: Chung, Shiu-Dong, et al.
Publicado: (2017)

Obesity and the Odds of Weight Gain following Androgen Deprivation Therapy for Prostate Cancer
por: Braunstein, Lior Z., et al.
Publicado: (2014)

Impact of androgen-deprivation therapy on the outcome of dose-escalation prostate cancer radiotherapy without elective pelvic irradiation
por: Hou, Wei-Hsien, et al.
Publicado: (2017)

Molecular Markers in Sex Hormone Pathway Genes Associated with the Efficacy of Androgen-Deprivation Therapy for Prostate Cancer
por: Yu, Chia-Cheng, et al.
Publicado: (2013)

The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment
por: Ku, Ja Yoon, et al.
Publicado: (2015)

Androgen deprivation therapy for prostate cancer: indications, contraindications and possible consequences
por: Karl, Alexander, et al.
Publicado: (2009)

Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer
por: Røe, Kathrine, et al.
Publicado: (2012)

Prostate Carcinogenesis with Diabetes and Androgen-Deprivation-Therapy-Related Diabetes: An Update
por: Hara, Noboru
Publicado: (2012)

Androgen-deprivation therapy-induced aggressive prostate cancer with neuroendocrine differentiation
por: Lipianskaya, Julia, et al.
Publicado: (2014)

Adverse Effects of Androgen Deprivation Therapy for Prostate Cancer: Prevention and Management
por: Sountoulides, Petros, et al.
Publicado: (2013)

Effect of androgen deprivation therapy on cardiovascular risk factors in prostate cancer
por: Roayaei, Mahnaz, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_vvbjrdjai05ueukd82i57h9ato